Vlastnictví managementu společnosti Hutchison China MediTech
Jaká je hodnota metriky Vlastnictví managementu společnosti Hutchison China MediTech?
Hodnota metriky Vlastnictví managementu společnosti Hutchison China MediTech Ltd. je 43.90%
Jaká je definice metriky Vlastnictví managementu?
Vlastnictví managementu (Insider Ownership) je poměr akcií vlastněných akcionáři v rámci firmy (akcionáři, kteří vlastní více než 5% společnosti nebo ve funkci ředitele či vedoucího odddělení) a veškerých vydaných akcií.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Vlastnictví managementu společností v sektoru Health Care sektor na LSE ve srovnání se společností Hutchison China MediTech
Čemu se věnuje společnost Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Firmy s metrikou vlastnictví managementu podobnou společnosti Hutchison China MediTech
- Hodnota metriky Vlastnictví managementu společnosti Techgen Metals Ltd je 43.86%
- Hodnota metriky Vlastnictví managementu společnosti Dunelm Plc je 43.89%
- Hodnota metriky Vlastnictví managementu společnosti Membership Collective je 43.89%
- Hodnota metriky Vlastnictví managementu společnosti CRCAM d'Ille et Vilaine je 43.89%
- Hodnota metriky Vlastnictví managementu společnosti Boomer je 43.89%
- Hodnota metriky Vlastnictví managementu společnosti FastForward Innovations je 43.90%
- Hodnota metriky Vlastnictví managementu společnosti Hutchison China MediTech je 43.90%
- Hodnota metriky Vlastnictví managementu společnosti Rizhao Port Jurong Co je 43.90%
- Hodnota metriky Vlastnictví managementu společnosti Rizhao Port Jurong Co je 43.90%
- Hodnota metriky Vlastnictví managementu společnosti China Assurance Finance je 43.91%
- Hodnota metriky Vlastnictví managementu společnosti Zoned Properties je 43.91%
- Hodnota metriky Vlastnictví managementu společnosti Quantum Blockchain Technologies je 43.92%
- Hodnota metriky Vlastnictví managementu společnosti GMP Capital je 43.92%